We have previously reported that a subset of breast tumors are infiltrated with IL-17A-producing tumor-associated lymphocytes and that IL-17A cytokine is principally associated with estrogen receptor negative (ER-) and triple negative, basal-like tumors. We established that IL-17A producing lymphocytes induced cancer cell proliferation, chemoresistance, and invasion, indicating that IL-17A is a potential therapeutic target for breast malignancies. © 2014 Landes Bioscience.
CITATION STYLE
Bastid, J., Bonnefoy, N., Eliaou, J. F., & Bensussan, A. (2014). Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. OncoImmunology. Landes Bioscience. https://doi.org/10.4161/onci.28273
Mendeley helps you to discover research relevant for your work.